Evidence map›Paper›PMID 42634082›Full record

ReviewSignal transduction and targeted therapy2026

The making of cells and organs in xenogeneic animal bioreactor.

Yunhan Tang, Ye Feng, Zhu Chen, Sai-Juan Chen, Lin Cheng

Abstract readReview
In one paragraph

Review in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yunhan Tang *Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ye Feng *Shanghai YangZhi Rehabilitation Hospital (Shanghai Sunshine Rehabilitation Center), Tongji University School of Medicine, Shanghai, China.
Zhu ChenShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. zchen@stn.sh.cn.
Sai-Juan ChenShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. sjchen@stn.sh.cn.ORCID 0000-0003-3789-1284
Lin ChengShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. lincheng@shsmu.edu.cn.ORCID 0000-0002-3688-9863

Funding

Shanghai Municipal Education Commission 22SG12
6 · The paper itself

Abstract

abstactFor patients with end-stage organ dysfunction, organ transplantation is the only viable treatment option. However, the most significant challenge at present is the severe shortage of donor organs, and no technology exists that allows for long-term, sustainable organ generation. The utilization of xenogeneic animals as in vivo bioreactors constitutes a viable method for the generation of functional and transplantable cells, tissues, and organs in vivo. The primary technology, blastocyst complementation, involves the injection of donor pluripotent stem cells into an organogenesis-disabled host embryo. This allows donor stem cells to compensate for organ defects and ultimately generate tissues or organs derived from the donor. Recent advancements in the field have demonstrated the successful generation of xenogeneic tissues and organs in rodents and large animals through the utilization of blastocyst complementation techniques. In addition, the replacement of nephron progenitor cells in the kidneys can be achieved through the application of the organogenic niche method. Furthermore, the expansion of xenogeneic hepatocytes and blood cells in immunodeficient animals is a viable approach. In this review, we introduce the history of blastocyst complementation and the impact of the pluripotent state of stem cells, one of its elements, on chimeric efficiency. Additionally, we provide a synopsis of the research progress concerning the utilization of rodents, pigs, and cattle as in vivo bioreactors to generate xenogeneic cells, tissues, and organs. Finally, the potential opportunities, challenges, and prospects for generating human blood cells in pigs are discussed.

Indexed as

BioreactorsPluripotent Stem CellsTransplantation, HeterologousAnimalsBlastocystCattleHumansSwine

Identifiers

PMID42634082
PMCPMC13500850

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.